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Similarly efficacious anti‑malarial drugs
SJ733 and pyronaridine differ in their ability
to remove circulating parasites in mice
Arya SheelaNair1†, Aleksandra S. Romanczuk1†, Rosemary A. Aogo2†, Rohit Nemai Haldar1,
Lianne I. M. Lansink1,3, Deborah Cromer2, Yandira G. Salinas5, R. Kiplin Guy5, James S. McCarthy1,4,6,
Miles P. Davenport2†, Ashraful Haque1,3*† and David S. Khoury2*†

Abstract
Background: Artemisinin-based combination therapy (ACT) has been a mainstay for malaria prevention and treatment. However, emergence of drug resistance has incentivised development of new drugs. Defining the kinetics with
which circulating parasitized red blood cells (pRBC) are lost after drug treatment, referred to as the “parasite clearance
curve”, has been critical for assessing drug efficacy; yet underlying mechanisms remain partly unresolved. The clearance curve may be shaped both by the rate at which drugs kill parasites, and the rate at which drug-affected parasites
are removed from circulation.
Methods: In this context, two anti-malarials, SJ733, and an ACT partner drug, pyronaridine were compared against
sodium artesunate in mice infected with Plasmodium berghei (strain ANKA). To measure each compound’s capacity
for pRBC removal in vivo, flow cytometric monitoring of a single cohort of fluorescently-labelled pRBC was employed,
and combined with ex vivo parasite culture to assess parasite maturation and replication.
Results: These three compounds were found to be similarly efficacious in controlling established infection by reducing overall parasitaemia. While sodium artesunate acted relatively consistently across the life-stages, single-dose
SJ733 elicited a biphasic effect, triggering rapid, partly phagocyte-dependent removal of trophozoites and schizonts,
followed by arrest of residual ring-stages. In contrast, pyronaridine abrogated maturation of younger parasites, with
less pronounced effects on mature parasites, while modestly increasing pRBC removal.
Conclusions: Anti-malarials SJ733 and pyronaridine, though similarly efficacious in reducing overall parasitaemia in
mice, differed markedly in their capacity to arrest replication and remove pRBC from circulation. Thus, similar parasite
clearance curves can result for anti-malarials with distinct capacities to inhibit, kill and clear parasites.
Keywords: SJ733, Pyronaridine, Artesunate, Plasmodium berghei, Parasite clearance
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Background
Malaria is caused by protozoan parasites from the genus
Plasmodium, which cyclically invade, replicate within
and rupture out of red blood cells (RBC) in the host.
There were an estimated > 200 million cases of malaria
and > 400,000 deaths annually between 2015 and 2020
[1]. Artemisinin-based combination therapy (ACT) has
been the recommended first-line treatment for malaria
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for several years [2]. However, emergence of parasite
resistance to artemisinin-based combinations is threatening progress towards malaria elimination [3]. This has
prompted development of both new artemisinin-based
combinations and new candidate anti-malarial drugs.
The kinetics of circulating parasitized red blood cells
(pRBC) after anti-malarial drug treatment is commonly
referred to as the “parasite clearance curve” (PCC). It
has been a useful proxy for determining parasiticidal and
clinical efficacy of drug candidates [4]. However, ex vivo
culture of pRBC from Plasmodium falciparum-infected,
artesunate-treated human volunteers has recently been
used to demonstrate that parasites are rendered non-viable well before any detectable change in the PCC [5]. This
revealed a disconnect, and possibly an under-estimation,
of anti-malarial drug efficacy when the principal metric
is the PCC. It has recently been proposed that the PCC
is a composite of parasiticidal/parasitostatic drug effects
and removal of pRBC [4]. Hence, the hypothesis here is
that two highly effective anti-malarials can reduce total
parasite numbers by the same magnitude, yet differentially remove and/or arrest the development of circulating parasites.
Previously, experimental and mathematical modelling approaches have been developed for quantifying
parasite replication and pRBC removal in mice [6–9].
This involved flow cytometric tracking over time of a
cohort of fluorescently-labelled pRBC [10], thereby permitting observation of maturation, schizogony, and loss
of the first generation of parasites, and emergence of
subsequent generations. Using this approach revealed
instances where immune responses controlled parasite numbers without removing pRBC [6, 9], and where
two licensed anti-malarial drugs, sodium artesunate and
mefloquine, permitted drug-affected parasites to persist in circulation [7, 8]. Moreover, mefloquine-affected
pRBC were removed more slowly than artesunateaffected pRBC, suggesting not all drugs are equivalent at
inducing removal of drug affected pRBCs.
Here, two important anti-malarial compounds, SJ733
and pyronaridine were examined [11, 12]. SJ733 is an
inhibitor of P. falciparum ATP4, a sodium-proton antiporter. Recent first-in-human trials revealed rapid,
though un-sustained, disappearance of parasites from
circulation with a clearance half-life of ~ 4–7 h [13],
supporting SJ733 as a possible partner drug for longeracting anti-malarial drugs. SJ733 was also reported to be
amongst a small number of anti-malarial drugs known
for their ability to increase the rigidity of pRBC, potentially increasing susceptibility to splenic removal [14, 15].
Pyronaridine is a potent anti-malarial with a long history
of clinical use, particularly in China. It has a long halflife [12], has been reported to cause fast reduction in

Page 2 of 10

pRBC numbers in mice [16], and has faster in vitro activity compared with many other long acting anti-malarial
drugs [17]. Pyronaridine was recently developed as a
long-lasting partner drug in ACT [1, 18, 19]. Here, Plasmodium berghei (strain ANKA) infection of mice was
used to examine the in vivo dynamics of pRBC killing and
removal after drug treatment. While SJ733 and pyronaridine similarly reduced total parasite numbers by 24 h
post-treatment, pRBC removal rates and killing kinetics were distinct. SJ733 rapidly removed mature stages,
leaving younger ring-stages to circulate, while pyronaridine rapidly inhibited ring-stages, allowing a portion of
mature parasites to complete one transition to the next
generation of RBC, while only modestly increasing RBC
removal.

Methods
Experimental mice and blood‑stage Plasmodium infection

C57BL/6 J mice were purchased from the Animal
Resource Centre (Perth, Australia). All mice were
female between 6 and 12 weeks of age and were maintained under conventional conditions. This study was
carried out in strict accordance with guidelines from
The National Health and Medical Research Council
(NHMRC) of Australia. All animal procedures and protocols were approved (A02-633 M and A1503-601 M)
and monitored by the QIMR Berghofer Medical Research
Institute Animal Ethics Committee. Plasmodium berghei
(strain ANKA) parasites, constitutively expressing highlevels of enhanced Green Fluorescence Protein (GFP),
were sourced and used as previously reported [9, 20, 21].
Plasmodium berghei parasites were used after defrosting
cryopreserved infected blood and a single in vivo passage
in C57BL/6 J mice. RBCs were collected from passage
mice by cardiac puncture and used to infect via lateral
tail vein injection.
Drug preparation and administration

Saline was used a negative control for all experiments
involving drug treatment. Sodium artesunate (Guilin
Pharmaceutical or sourced from J. Mohrle) was used
as a positive control and was prepared according to the
manufacturer’s protocol by dissolving in 5% sodium
bicarbonate solution, diluting in 0.9% saline (Baxter) to
a final concentration of 5 mg/ml. Mice were treated via
intraperitoneal injection (1 mg per 200 μl dose). SJ733
and pyronaridine (AssayMatrix) were dissolved in a drug
formulation consisting of ethyl alcohol, propylene glycol,
Carbowax® PEG 400, phosphate buffered saline (PBS)
(pH 7.4) and 2-hydroxypropyl-β-cyclodextrin (HβCD).
SJ733 solution was sonicated for 15 min and pyronaridine solution was placed on a roller for 15 min and then
sonicated for 5 min in order to yield clear solutions.

SheelaNair et al. Malaria Journal

(2022) 21:49

Both drugs were administered to mice by oral gavage.
Clodronate liposomes (Liposoma; www.clodronatelipos
omes.com) were used for depleting macrophages, as
previously described [6–8], and were injected three days
before infections with a single i.v. injection (200 μl, lateral
tail vein).
RBC adoptive transfer

Adoptive transfer of fluorescently-labelled RBC was performed as previously described [6, 9]. RBCs were collected from infected mice by cardiac puncture, washed
twice in Ca2+- and Mg2+-free PBS, and stained with viable cell dye CellTrace™ Far Red (CTFR; Thermo Fisher).
Briefly, 50 μg CTFR was dissolved for ten minutes in 25 μl
tissue culture grade dimethyl sulphoxide. This was added
to 5 ml of resuspended RBC in Ca2+- and Mg2+-free PBS.
RBC were stained in the dark, at room temperature with
constant rolling for 15 min, and washed twice in 10 × volumes of C
 a2+- and Mg2+-free PBS. CTFR-labelled RBCs
were resuspended in 2 ml Roswell Park Memorial Institute 1640 (RPMI) medium per donor mouse and injected
in 200 μl volumes to recipient mice via lateral tail vein.
Flow cytometry of RBC

Established flow cytometric methods [6–9] were
employed to track the first generation of pRBC, termed
Gen0 pRBC, and to distinguish these from subsequent
generations of pRBC (termed G
 en1+), which were identified as un-labelled, endogenous RBC infected with the
merozoite progeny of G
 en0 pRBC. This staining approach
also permitted assessment of parasite life-stages (ring,
trophozoite and schizont), as previously reported [6–
9]. Briefly, a single drop of blood from a tail bleed was
diluted and mixed in 200 μl of RPMI medium containing
5 U/ml heparin sulphate. Diluted blood was simultaneously stained for 30 min in the dark at room temperature with cell-permeant RNA/DNA stain, Syto84 (5 μM;
Life Technologies) and with DNA stain, Hoechst 33342
(10 μg/ml; Sigma). Staining was quenched with 10 volumes of ice-cold RPMI medium, and samples immediately analysed by flow cytometry using an LSRII Fortessa
analyser (BD Biosciences) and FlowJo software (Treestar,
CA, USA). FSC-Area (FSC-A) and FSC-Height (FSC-H)
were used to exclude doublets (the result of two cells
being detected simultaneously by the flow-cytometer).
FSC-A and side scatter (SSC-A) were used to distinguish
RBCs from debris and white blood cells on the basis of
size and granularity. Infected RBCs were detected as coexpressing Hoechst 33342 and Syto84, with expression
of either one alone being insufficient to identify the presence of parasites. Adoptively-transferred 
Gen0 pRBCs
were readily distinguished from endogenous RBC, and
importantly from Gen1+ pRBC, by CTFR-labelling.
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Ex vivo culture

Tail blood was collected from mice into 1.5 ml Eppendorf
tubes with culture medium consisting of 80% RPMI, 20%
fetal bovine serum (FBS) and 1/1000 heparin and 200 μl
was plated per well in 96 well plates. Plates were covered
then flushed for 30 s with 5% CO2, 5% O2, 90% N2 in a
closed secondary container which was then incubated at
37 °C.
Statistical analysis

All comparisons of groups were performed using a t
test. A one-way analysis of variance (ANOVA) was used
to compare means from more than 2 groups. Multi-way
ANOVA was used to compare groups when there were
multiple variables, in particular to assess whether there
was an interaction between clodronate treatment and
drug treatment. All data analysis was performed in MATLAB version R2020a. All summary statistics in the text
are provided as arithmetic mean and standard deviations.
A logistic growth model was used to estimate the viable
parasites 24 h after treatment, by fitting growth of parasitaemia. The model has the form,

P(t) =

C0 P0 eg(t−t0 )


C0 + P0 eg(t−t0 ) − 1

where P is the parasitaemia at time, t , C0 is the saturating level of parasitaemia (as time approaches infinity),
P0 is the parasitaemia at a specified initial time t0 and g
is the initial growth rate (i.e. at time t0) of parasites. The
constant e is the mathematical constant. Logistic growth,
rather than simple exponential growth, was used to
model this data because growth of parasitaemia is saturating, likely due to target cell limitation [22]. The built
in function lsqnonlin was used to fit this model to the
growth of parasitaemia after treatment in MATLAB. In
addition, the parasite clearance half-lives were estimated
by fitting each individual mouse decline curve on a logscale with a linear regression model, using the function
fitlm in MATLAB. The half-life was calculated as log(2)
divided by the slope of the log-linear decline.

Results
SJ733 and pyronaridine are similarly efficacious
at reducing parasitaemia in P. berghei‑infected mice

Firstly, it was confirmed that SJ733 and pyronaridine rapidly reduce circulating parasitaemia in mice. C57BL/6 J
mice, 5 days after infection with P. berghei, generally
exhibited a parasitaemia exceeding ~ 2% (Fig. 1). Liver
damage is apparent by this stage of infection, although
severe neurological and pulmonary complications are
yet to develop [23]. Mice were treated with a single dose
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Fig. 1 SJ733 and pyronaridine are similarly efficacious at reducing
parasitaemia in 5-day P. berghei-infected mice. C57BL/6 J mice (n = 6/
group) were infected with blood-stage P. berghei (strain ANKA)
parasites, individually monitored for blood parasitaemia daily from
day 4 post-infection (p.i.), and treated with single dose anti-malarials
SJ733, pyronaridine or sodium artesunate on day 5 p.i. (indicated
with vertical dotted line). Control saline treated mice were ethically
euthanised due to severe symptoms on day 6 p.i

of SJ733 (200 mg/kg), pyronaridine (10 mg/kg, doses
established from in vivo titration studies), or the rapidly
acting drug, sodium artesunate (50 mg/kg) as a positive
control, and fold-reductions in parasitaemia determined
24 h after treatment relative to saline controls. All control
mice (i.e., saline treated mice) exhibited clinical scores
requiring ethical euthanasia at day 6 (as expected for
this severe and lethal model [24]), whereas none of the
artesunate, SJ733 or pyronaridine-treated mice showed
neurological complications over this time period. Parasitaemia following treatment with sodium artesunate
declined 1.6 ± 0.25 fold over the first 24 h (Fig. 1). The
fold-decline for SJ733 and pyronaridine was 2.1 ± 0.38
and 2.5 ± 0.26, respectively. This confirmed anti-malarial
drug efficacy for SJ733 and pyronaridine in this experimental malaria model. Further, these results demonstrate
that at the doses used, these two drugs exhibited greater
reductions in pRBC over the first 24 h than sodium
artesunate (P = 0.0079 and P = 0.0003), despite the very
high dose of sodium artesunate [8].

SJ733 substantially increases pRBC removal

Since the decline in parasitaemia is a composite measure of pRBC removal and parasite replication, the established RBC adoptive transfer approach [6–9] was used
to directly measure whether SJ733 had altered the rate
of pRBC removal from circulation. Mice were infused
with fluorescently-labelled RBC containing P. bergheiGFP parasites, and were immediately treated with SJ733
(200 mg/kg), sodium artesunate (50 mg/kg) or control
saline (Fig. 2A). Flow cytometric assessment of peripheral blood was then conducted to monitor the fate of
fluorescent pRBC. Parasites observed in their original,
fluorescent RBC were considered “Generation 0” ( Gen0).
Parasites observed in non-fluorescent RBC, judged to
have invaded new RBC, were termed “Generation 1 + ”
(Gen1+) (Fig. 2A, B). In the absence of anti-malarial
drugs, the expected gradual loss of Gen0 pRBC, due to
maturation, rupture and phagocytic removal and concomitant emergence of G
 en1 pRBC was observed. In contrast to previous studies [6–9], Gen0 pRBC were lost from
circulation at a substantially higher rate after SJ733 treatment compared to saline controls, specifically over the
first seven hours post-treatment, termed Phase I (Fig. 2C,
D). By 7 h post-treatment, ~ three-fold fewer Gen0 pRBC
(32.2% ± 9.7) remained in circulation in SJ733-treated
mice compared to either saline control mice (91.0% ± 4.6,
P = 0.0002) or sodium artesunate-treated mice (94.2% ±
6.2, P = 0.0009) (Fig. 2C, D). Thus SJ733, in contrast to
artesunate, substantially increased the rate of pRBC
removal within the first 7 h after treatment.
After the initial 7 h period, Gen0 pRBC appeared to
persist and plateau in SJ733-treated mice, which contrasted with the continued, gradual loss observed in
control saline-treated mice, and with the previously
reported persistence of drug-affected parasites in sodium
artesunate-treated mice (Fig. 2C, D). Nevertheless, by
25 h Gen0 pRBC concentrations were similar between
drug-treated groups. This indicated that although SJ733
induced a rapid Phase I of pRBC removal, a Phase II also
occurred (7–25 h), in which G
 en0 pRBC persisted longer
than in control-treated mice (Fig. 2C, D). The biphasic
dynamics for Gen0 pRBC after SJ733 treatment was distinct from that of sodium artesunate, illustrating differing drug effects on pRBC in vivo. Interestingly, the pRBC
removal rate in the first 7 h was higher with SJ733 than
other previously reported treatments or immunological
interventions [6–9].
SJ733 targets late‑stage pRBC for rapid removal

The biphasic kinetics with which Gen0 pRBC were lost
from circulation after SJ733 treatment suggested possible heterogeneous effects on parasites. Flow cytometric
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Fig. 2 SJ733 rapidly removes blood-stage parasites from circulation. A Schematic showing C57BL/6 J mice (n = 6/group) administered C TFR+ RBC
harbouring P. berghei-GFP (termed Gen0), treated immediately with control saline, sodium artesunate or SJ733, and peripheral blood monitored
individually at times indicated by flow cytometry to monitor Gen0 pRBC and emergence of G
 en1+ pRBC. B Flow cytometric gating strategy for
identifying Gen0 and Gen1+ pRBC and assessing parasite life-stages. C Representative FACS plots for total RBC over time, showing the dynamics of
Gen0 and Gen1+ pRBC. D Summary of G
 en0 and G
 en1+ pRBC dynamics expressed as a percentage of total RBC. Error bars represent the standard the
standard error of the mean

assessment of DNA and RNA content within pRBC
permitted categorization into three stages of maturation [10]. At the time of transfer into mice, G
 en0 pRBC
exhibited a spectrum of maturation states (Fig. 3A).
SJ733 treatment induced a pronounced loss of trophozoites and schizonts during Phase I (Fig. 3A, B), which
contrasted with increases in these life-stages in control
mice (P < 0.0001) (Fig. 3B). A two-point clearance halflife revealed that late-stage parasites were lost with a net
half-life of 3.0 ± 1.0 h during this window. These data
indicate that the rapid removal of parasites induced by
SJ733 treatment in Phase I is primarily the result of rapid
removal of mature trophozoite and schizont forms.
The original murine study of SJ733 efficacy used mice
that were splenectomized or phagocyte depleted via clodronate liposomes (in the humanized mouse model—
NOD-scid IL2Rgnull mice infected with P. falciparum)
and found that the rapid effect of SJ733 within the first
12 h after treatment was not strongly dependent upon the
presence of a spleen or splenic phagocytes [11]. This was
further explored here by determining the effect of clodronate liposomes on SJ733-mediated removal of Gen0

pRBC within 7 h after treatment. Firstly, consistent with
previous reports [7, 8], after clodronate treatment alone
Gen0 pRBC remained in circulation for longer (Fig. 3C,
D), indicating the efficacy of the phagocyte depletion regimen used here. Next, it was found that although SJ733
caused a rapid loss of G
 en0 pRBC in clodronate-treated
mice, the magnitude of this effect was reduced (Fig. 3D,
fold-drop in Gen0 over 7 h exhibited significant interaction between SJ733 treatment and clodronate in two-way
ANOVA, P = 0.0042). Given that clodronate treatment
removes splenic macrophages effectively [7, 8], the data
reported here support only a partial role for these cells
in rapid removal of SJ733-affected G
 en0 pRBC from
circulation.
Parasiticidal efficacies of SJ733 and sodium artesunate are
similar despite differences in pRBC removal

During Phase II after SJ733 treatment (Fig. 2D), more
Gen0 pRBC remained compared to controls by 25 h
(P = 0.0001, 17.4 ± 2.0% versus 6.9 ± 2.8% of the initial
proportions at 1 h), suggesting SJ733 had impaired or
inhibited Gen0 pRBC maturation (Fig. 3B). To determine
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Fig. 3 SJ733 targets mature life-stages for early removal, with a partial requirement for phagocytes. A Representative FACS plots showing life-stage
gating for rings, trophozoites and schizonts in Gen0 pRBC over time. Mice (n = 6/group) were administered C TFR+ RBC harbouring P. berghei-GFP
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maturation potential of 
Gen0 pRBC surviving Phase
I, RBC were harvested at 7 h after SJ733 treatment and
cultured ex vivo (Fig. 4A). This revealed the majority of
residual parasites did not mature into schizonts over 15 h
of ex vivo culture (5.4 ± 0.8% of SJ733-exposed parasites
reached schizont stage, compared with 54.0 ± 0.7% for
saline controls, P < 0.0001) (Fig. 4B, C), but were capable
of partial maturation as evidenced by an increase in lifestage dependent GFP expression (Fig. 4B).
In vivo parasite regrowth was observed in SJ733treated mice, similar to that seen after sodium artesunate treatment, which indicated that a proportion of
parasites had progressed to schizogony after single-dose
treatment with either drug (Fig. 4D). Modelling in vivo
regrowth of parasitaemia suggested that SJ733 had
reduced viable parasitaemia by 98.4% (95% CI 96.0, 99.3)
of that observed in control mice 24 h after treatment.
Similarly, a single dose of sodium artesunate reduced
viable parasitaemia by 96.7% (95% CI 92.0, 98.7) of that
in control mice. Therefore taken together, this data reveal
that although SJ733 triggered a unique, rapid removal of

late-stage pRBC, by slowing maturation and impairing
schizogony, the overall effect on viable parasite numbers
24 h after treatment was similar for SJ733 and artesunate,
with both treatments causing persistence of pRBC in
Gen0.
Pyronaridine abrogates maturation, increases removal
of drug‑affected ring‑stages, and cures established P.
berghei infection

Pyronaridine showed a similar decline in parasitaemia
over the first 24–48 h period compared to SJ733 (Fig. 1).
Hence the effects of this drug on pRBC clearance and parasite killing was also examined. Following pyronaridine
treatment, a modest increase in the loss of G
 en0 pRBC
compared to controls was apparent by 12 h post-infection (Fig. 5A). Despite the loss of Gen0 pRBCs at a similar
or faster rate compared to untreated controls, ring-stage
parasites persisted in the first 7 h after treatment compared with controls (Fig. 5B), suggesting that ring-stage
parasites had been rapidly inhibited by pyronaridine. To
test this, Gen0 pRBCs collected 7 h after in vivo treatment
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Fig. 4 SJ733 arrests maturation and replication in ring-stage parasites. A Schematic showing that 7 h after G
 en0 pRBC adoptive transfer into mice
(n = 5/group) and SJ733, artesunate or control saline treatment, peripheral blood was cultured ex vivo to determine the capacity of remaining
drug-exposed Gen0 pRBC to mature and undergo schizogony. B Representative FACS plots depicting schizogony with Hoechst33342 staining in
Gen0 pRBC over 15 h of culture, starting at 7 h post-in vivo drug exposure. C Summary graph for individual mice, showing percentage of G
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that were schizonts before and after ex vivo culture. D A logistic growth model fit to saline-treated controls (black), 50 mg/kg, artesunate (blue), and
200 mg/kg, SJ733 (red)-treated infections. The model was used to estimate the number of viable parasites remaining 24 h after treatment

with pyronaridine were cultured in vitro, and, similar
to artesunate, it was observed that maturation had been
abrogated, with parasites in fact losing life-stage dependent GFP expression (54.6 ± 1.0% drop in the mean florescence intensity of GFP (GFP-MFI), P < 0.0001) (Fig. 5C,
D). In contrast, parasites from control mice showed a
7.3 ± 0.35 fold increase in GFP-MFI over 15 h of in vitro
culture. Since ring-stage development had been inhibited
by 7 h in vivo treatment the authors inferred that the loss
of pRBC in vivo at later time points was due to removal
of ring-stage pRBC and estimated the half-life of removal
of rings after pyronaridine treatment to be 4.0 ± 0.21 h
(Fig. 5B). In contrast to rapid ring-stage inhibition, it
was evident that a portion of trophozoites and schizonts
were not inhibited from rupturing and producing G
 en1
parasites up until 19 h post-treatment. Thus, while the
majority of parasites remaining at 24 h after artesunate or
SJ733 treatment were Gen0 pRBC, in mice treated with
pyronaridine these were mostly G
 en1 pRBC. This suggested pyronaridine exhibited rapid action on ring-stage
parasites in vivo, but was less effective at rapidly blocking schizogony and subsequent invasion compared with
artesunate and SJ733. Finally, no recrudescence of infection after single dose pyronaridine was observed. Thus,
unlike other drugs tested, including sodium artesunate,

mefloquine or SJ733, a single dose of pyronaridine cured
a high inoculum P. berghei infection. Taken together,
these results indicate that the longer-acting pyronaridine
rapidly inhibits ring-stage maturation, accelerates their
removal, and ultimately elicited single-dose cure in this
lethal murine model.

Discussion
In this study, a blood-stage Plasmodium infection model
in mice was used to provide mechanistic detail on how
the anti-malarial drugs SJ733 and pyronaridine induce
rapid loss of pRBC in vivo. Having confirmed that these
two drugs were no less effective than artesunate at reducing parasitaemia in this murine model, two parameters
were examined in this study: firstly, the rate at which
pRBC were removed from circulation after drug treatment, and secondly, parasite replicative fitness via the
capacity to mature within RBC and to give rise to the
next generation of pRBC. These two parameters cannot
be readily inferred from longitudinal parasitaemia measurements alone.
Recent first-in-human trials indicated that SJ733 was
well-tolerated, had a good safety profile, and caused a
rapid, though unsustained, reduction in parasite numbers after a single-oral dose [13]. The in vivo mechanism

Gen0

0.25
0.20
0.15
0.10
0.05
0.00

1

7

13

19

Hours p.i.

C

25

Saline

B

Pyronaridine

Gen1+

1.0

0.6
0.4
0.2
1

7

13

19

Hours p.i.

Artesunate

0.15
0.10
0.05
0.00

25

1

7

13

19

Hours p.i.

D 100

Pyronaridine

1.53

1.61

Rings

0.20

0.8

0.0

Saline

1.71

25

Artesunate

Pyronaridine

Trophozoites

0.20
0.15
0.10
0.05
0.00

1

7

13

19

Hours p.i.

25

% schizonts (% of total RBC)

Artesunate

Page 8 of 10

%Rings (% Total RBC)

Saline

Gen1 pRBC (% of total RBC)

Gen0 pRBC (% of total RBC)

A

(2022) 21:49

% trophozoites (% of total RBC)

SheelaNair et al. Malaria Journal

Schizonts

0.20
0.15
0.10
0.05
0.00

1

7

13

19

Hours p.i.

25

7h
22h

80

45.5

5
10

Hoechst

22h

2.59

5
10

4
10

4
10

3
10

3
10

3
10

0

0

0

0

GFP

10

3

10

4

10

5

0

10

3

10

1.12

5
10

4
10

4

10

5

% Schizonts

7h

60

40

20

0

10

3

10

4

10

5

0

Saline

Artesunate Pyronaridine

Fig. 5 Pyronaridine arrests maturation in ring-stages and modestly increases pRBC removal. A Summary of G
 en0 and Gen1+ pRBC dynamics
expressed as a percentage of total RBC after single dose treatment with pyronaridine, artesunate or control saline (n = 5 mice/group). B Summary
dynamics for Gen0 rings, trophozoites and schizonts expressed as a percentage of all RBC. C Representative FACS plots depicting schizogony with
Hoechst staining, and GFP expression in Gen0 pRBC over 15 h of culture, starting at 7 h post-in vivo drug exposure. D Summary graph for individual
mice, showing percentage of Gen0 pRBC that were schizonts before and after ex vivo culture. Error bars represent the standard the standard error of
the mean

of action inferred from the initial murine study, suggested that SJ733 affects all life-stages, and that rapid loss
of pRBC occurs without a requirement for the spleen or
phagocytes [11]. The data in the present study provides
further detail, by revealing that SJ733 elicits its effect in
two phases. During Phase I (0–7 h post-treatment), SJ733
caused rapid removal of late-stage pRBC. In contrast to
the limited increase in removal of pRBCs observed previously with other compounds [7, 8], the present data
has confirmed that pRBC removal can be substantially
enhanced in vivo by the action of some compounds. During Phase II, after 7 h exposure to SJ733, residual ringstage parasites were partially impaired from maturing
into trophozoites and schizonts. In addition, while clodronate liposome-treatment did not entirely abrogate
removal of late-stage pRBC, the efficacy of this process
was reduced significantly. Clodronate has been shown to
remove splenic macrophages more so than Kupffer cells
in the liver [7, 8], suggesting that SJ733 may partially
rely on host splenic macrophages to remove late-stage
pRBC. This evidence for a partial role of phagocytosis
must be interpreted with caution as it is difficult to discern from the lower overall clearance observed in clodronate treated mice. Together, the data presented here is
consistent with SJ733 acting on all life-stages in vivo, but

emphasises that the removal of drug-affected parasites is
dramatically different for early and late-stages.
Interestingly, clearance of parasites after artesunate and
SJ733 was rapid, the estimated drop in viable parasites
(based on regrowth of parasitaemia) was greater than
the drop in total circulating parasitaemia (Fig. 4D). This
is consistent with observations that parasites are killed
by artesunate more quickly than they are removed by the
host [5].
A limitation of the infection model employed in this
study (P. berghei strain ANKA in C57BL/6 J mice), compared with a humanized mouse model of infection is that
it was not possible to study a human parasite species, and
drug inhibitory effect may vary between parasite species.
However, given the aim of this study is to understand
parasite clearance after drug treatment, it was reasoned
that the use of mice with intact circulatory, immune
and mononuclear phagocytic systems should be prioritized, which precluded the use of a humanized mouse
model. Interestingly, the observation here of rapid splenic
removal of drug-affected late-stage parasites is not a phenomenon that could be observed in human P. falciparum
infection because late-stage parasites are sequestered in
the microvasculature in human infection and so such
rapid removal is not expected to occur. Thus, in humans
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the decline in parasitaemia would be expected to be governed predominately by ongoing development of some
ring-stage parasites into trophozoites, which sequester
and/or are removed by the spleen.
Pyronaridine induced a faster loss of pRBCs from circulation than artesunate and a rapid inhibition of parasite development, but failed to abrogate the appearance
of the next generation of parasites. This combination of
rapid clearance yet imperfect inhibition of schizogony
and invasion is an interesting property of the drug. Similar to SJ733, pyronaridine induced a rapid loss of latestage parasites; given next generation (Gen1+) parasites
were observed after treatment, this may have occurred
due to both rupture of schizonts as well as clearance of
parasites. Pyronaridine also rapidly inhibited ring-stage
parasites, and increased their clearance. This was surprising given that the reported mechanisms of action of
pyronaridine are believed to be on trophozoite stages and
formation of haemozoin [25]. In vitro studies suggested
that haematin and pyronaridine interactions accelerate
red cell lysis [25], and the authors speculate that the rapid
loss of ring and late-stage parasites in this murine system
may be partially due to enhanced lysis of RBCs. Pyronaridine is unique in its ability to cure established (i.e. day
5) P. berghei infection in mice. This is consistent with
findings of numerous other murine studies (reviewed in
[12]), where high cure rates were reported in mice treated
with pyronaridine, even when compared with other longacting compounds, an effect that is likely attributed to a
combination of the long half-life of the drug and its low
IC50 compared with other long-acting compounds.
The experimental models used in this study were
designed to test basic questions of how pRBC numbers
could be rapidly lowered during malaria. In this study,
three anti-malarials producing similar declines in total
parasitaemia after 24 h are demonstrated to achieve this
by distinctly different underlying kinetics of growth inhibition and pRBC clearance. In the animal model with
intact circulatory, immune and mononuclear phagocytic
systems examined here, it was demonstrated that pRBC
removal rates can be increased in vivo, as evidenced
by SJ733, which accelerates late-stage pRBC removal,
and pyronaridine which accelerates early-stage pRBC
removal. These two drugs were therefore unlike sodium
artesunate, which permits drug-affected parasites to
remain in the circulation for longer, and did not substantially increase the rate of removal by host phagocytes [7,
8].

Conclusions
In summary, in the murine infection model reported
here, accelerated pRBC removal, either by lysis or splenic
filtration, and abrogation of maturation and prolonged
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action in vivo, are major determinants of the clearance of
parasitaemia after treatment, and that these kinetics vary
considerably amongst compounds with different modes
of action.
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